A new report suggests that differences in albuminuria might contribute to disparities in susceptibility to nephropathy in African American and white individuals. Interpretation of this finding requires consideration of renal histology, clinical trials and genetic studies. These factors indicate that a far more complex scenario is likely to exist than previously thought.
1
Albuminuria and microalbuminuria were significantly more common in African American than in white individuals in this populationbased study, and were associ ated with racial differences in progres sion to ESRD. This observation would be particularly useful if albuminuria was readily treatable and normalization of albumin levels stabilized renal function in African Americans.
The mechanisms underlying progressive nephropathy in the setting of albuminuria in African Americans could not be deter mined in the epidemiological report by McClellan and colleagues. However, an analysis of the Dallas Heart Study reveals that genetic variation in apolipoprotein L1 (APOL1) underlies albuminuria and nephro pathy progression in this popula tion. 2 Results of the REGARDS analysis complement those of the Dallas Heart Study as both studies were populationbased. Unfortunately, APOL1 genotypes were not available in REGARDS and albuminuria and glomerular filtration rate (GFR) were used as surrogate intermediate markers of nephropathy progression.
Although albuminuria can be associated with progression of renal disease across races, the underlying patho genesis may differ between races. Albuminuria exhibits variable relation ships with nonrenal pheno types in African American and white indivi duals. For example, although albumin uria and microalbuminuria are accepted risk factors for cardiovascular disease, they differ entially associate with subclinical athero sclerosis in African American and white individuals with diabetes mellitus. 3 In the case of nephropathy, many non diabetic African Americans with lowlevel albuminuria, reduced GFR and hyper tension have kidney disease ascribed to essential hypertension without confirma tion by biopsy. 4 However, the histo pathology of renal lesions in putative hypertensive nephropathy differs between individuals of different races. Compared with white indivi duals, African Americans have signifi cantly higher frequencies of solidified glomerulo sclerosis, interstitial fibrosis and vascular lesions, which do not correlate with sys temic blood pressure despite equivalent proteinuria and hypertension. Essential hyper tension is unlikely to be the cause of progressive kidney disease or albuminuria in many of these African Americans. 4 Lowering systemic blood pressure and use of angiotensinconvertingenzyme (ACE) inhibitors often reduce albumin uria. However, abundant evidence indicates that these treatments do not reduce nephro pathy progression to an equal extent in hypertensive African American and white individuals without diabetic nephropathy or glomerulonephritis. The Hypertension Detection and FollowUp Program 5 and Multiple Risk Factor Intervention Trial 6 revealed that blood pressure reduction was less effective in slowing nephropathy pro gression in African American than in white individuals. The African American Study of Kidney Disease and Hypertension (AASK) evaluated ACE inhibitors and intensive hypertension control. 7 AASK demonstrated that ACE inhibition and use of low blood pressure targets led to slight reductions in the rate of renal function loss compared with usual blood pressure control and use of other antihypertensive drug classes. After completing the trial phase, the investiga tors of AASK administered universal ACE inhibition and applied low blood pressure targets to all participants who did not reach a trial end point. Ultimately, 60% of these individuals reached dialysis initiation, doubling of serum creatinine or death. As such, these interventions were not broadly effective. Strikingly, African Americans in REGARDS were more likely than white participants to receive ACE inhibitors, yet they still had more albuminuria. 1 The major question arising from REGARDS is whether reducing albuminuria leads to equal reduc tions in ESRD among African American and white individuals.
What factors are likely to account for racial differences in nephropathy pro gression associated with albuminuria?
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McClellan and colleagues proposed that elevated blood pressure, risk factors for cardiovascular disease, obesity, metabolic syndrome, smoking, vitamin D levels, geographic origin, lower socioeconomic class and low birth weight are potentially related. 1 Gene polymorphisms were also included on this list, as evidence supports the major contribution of two coding variants in APOL1 on racially variable risk for development and progression of non diabetic nephropathy. 2, 8 The impact of genetic risk associated with APOL1 is among the most impressive observed in complex disease. The odds ratio for APOL1 association with 'hypertension attributed' ESRD is 7.3, 10.5 in individuals with focal segmental glomerulosclerosis and >30 in those with HIVassociated col lapsing glomerulosclerosis. 9 Variants in APOL1 associated with nephropathy risk are essentially limited to the African American population, where one copy protects against African sleeping sickness. Approximately 39% of African Americans possess one APOL1 risk haplotype and 12% possess two risk haplotypes and are at high risk of ESRD. These polymorphisms are virtually absent in white individuals. 8 Racial differences in the frequencies of APOL1 risk variants explain the observed racial differences in nondiabetic nephro pathy. 2, 8 As such, genetic ancestry was likely the cause of the observations in REGARDS. When the investigators adjusted ESRD risk for the impact of GFR and albuminuria-an effect that attenuated the disparity in risk of ESRD between African American and white individuals-they were essentially adjust ing for the effect of APOL1. This concept is exemplified by the observa tion that donor kidneys from African Americans function for shorter periods after transplantation than donor kidneys from white individuals, an effect also related to APOL1 genotype. 10 By contrast, kidneys from African American donors lacking the two APOL1 risk haplo types function equally well as those from white individuals. Hence, donor APOL1 genotypes, and not race, confer nephro pathy risk. 10 Future studies should focus on the primary reasons for kidney failure, rather than intermediate outcomes such
''
It is now apparent that APOL1, and not albuminuria, is the major driver of racial disparities in ESRD '' as albuminuria and GFR. The association of genetic markers with albuminuria will become increasingly important.
Albuminuria should no longer be con sidered a modifiable risk factor for nephro pathy of equivalent significance in African American and white individuals. Generic efforts to reduce albuminuria in African Americans will soon be replaced by approaches that target the primary cause of albuminuria and subsequent nephropathy. ACE inhibitors and intensive blood pressure control do not markedly slow nephropathy progression in African Americans with low levels of albuminuria, 7 implying that reduc tion of albuminuria is insufficient. It is now apparent that APOL1, and not albumin uria, is the major driver of racial disparities in ESRD. As such, novel strategies based on genetic breakthroughs, which include the identification of genes commonly involved in nondiabetic nephropathy such as APOL1, podocin (NPHS2) and inverted formin2 (INF2), will need to directly target the pathogenesis of kidney disease and the associ ated albuminuria. In addition, results of epidemiological analyses can be extended by evaluation of causative genes and ancestry informative markers.
